Granahan Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Granahan Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-194,100	Closed	-$24M	–	266
2015 Q2	$24M	Hold	194,100	–	–	0.68%	52
2015 Q1	$22.9M	Hold	194,100	–	–	0.66%	57
2014 Q4	$23.1M	Hold	194,100	–	–	0.67%	57
2014 Q3	$21.8M	Hold	194,100	–	–	0.67%	59
2014 Q2	$18.4M	Hold	194,100	–	–	0.54%	74
2014 Q1	$13.7M	Sell	194,100 -194,000	-50%	-$15.4M	0.37%	108
2013 Q4	$28.8M	Hold	388,100	–	–	0.74%	47
2013 Q3	$29.4M	Sell	388,100 -40,700	-9%	-$3.24M	0.78%	42
2013 Q2	$34.3M	Buy	+428,800	New	+$31.6M	0.99%	22

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Granahan Investment Management's VRTX Position: Q3 2015 in Review

Granahan Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2015, closing a stake of 194,100 shares — an estimated $24M sold.

Granahan Investment Management first reported a position in VRTX in Q2 2013 and held it in 9 quarters. The position peaked at $34.3M in Q2 2013. 493 funds tracked by Wall St. Rank hold VRTX as of Q3 2015.

Granahan Investment Management reported no remaining Vertex Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Granahan Investment Management sold 194,100 Vertex Pharmaceuticals shares in Q3 2015, an estimated $24M.
Granahan Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Granahan Investment Management's Vertex Pharmaceuticals position peaked at $34.3M in Q2 2013.
493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2015.

Based on Granahan Investment Management's 13F filing for Q3 2015, filed 12 Nov 2015.